top of page
Advancing novel T-cell therapies in areas of unmet medical need
At Estrella, we are focused on discovering and developing novel T-cell therapies in areas of unmet medical need
Our approach is to advance our CD19-Redirected ARTEMIS T Cell programs in relapsed/refractory and high-risk blood cancers first. Meanwhile, we are also developing multiple pipeline candidates using the “mark-and-kill” approach to address various types of solid tumors, as well as specificity challenges previously thought impossible to overcome.
Diffuse large B cell lymphoma (DLBCL)
DLBCL and Acute lymphocytic leukemia (ALL)
Combination: EB103 + Oncolytic Virus
bottom of page